Key result
Myocardin optimally transactivates the human ACTG2 promoter by discriminating among juxtaposed CArG elements through a physical and functional partnership with the transcription factor NKX3.1.
Myocardin optimally transactivates the human ACTG2 promoter through specific CArG elements and a novel partnership with NKX3.1, driving smooth muscle cell differentiation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for smooth muscle differentiation mechanisms; leaves open relevance to human cardiovascular disease.
Serum response factor (SRF) is a ubiquitously expressed transcription factor that binds a 10-bp element known as the CArG box, located in the proximal regulatory region of hundreds of target genes. SRF activates target genes in a cell- and context-dependent manner by assembling unique combinations of cofactors over CArG elements. One particularly strong SRF cofactor, myocardin (MYOCD), acts as a component of a molecular switch for smooth muscle cell (SMC) differentiation by activating cytoskeletal and contractile genes harboring SRF-binding CArG elements. Here we report that the human ACTG2 promoter, containing four conserved CArG elements, displays SMC-specific basal activity and is highly induced in the presence of MYOCD. Stable transfection of a non-SMC cell type with Myocd elicits elevations in endogenous Actg2 mRNA. Gel shift and luciferase assays reveal a strong bias for MYOCD-dependent transactivation through CArG2 of the human ACTG2 promoter. Substitution of CArG2 with other CArGs, including a consensus CArG element, fails to reconstitute full MYOCD-dependent ACTG2 promoter stimulation. Mutation of an adjacent binding site for NKX3.1 reduces MYOCD-dependent transactivation of the ACTG2 promoter. Co-immunoprecipitation, glutathione S-transferase pulldown, and luciferase assays show a physical and functional association between MYOCD and NKX3.1; no such functional relationship is evident with the related NKX2.5 transcription factor despite its interaction with MYOCD. These results demonstrate the ability of MYOCD to discriminate among several juxtaposed CArG elements, presumably through its novel partnership with NKX3.1, to optimally transactivate the human ACTG2 promoter.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2009) studied this question. Myocardin optimally transactivates the human ACTG2 promoter by discriminating among juxtaposed CArG elements through a physical and functional partnership with the transcription factor NKX3.1.
Synapse has enriched 10 related papers. Consider them for comparative context: